Receptor-Targeted Therapies in Diabetes Mellitus: From Pathophysiology to Innovative Treatments
Series: Endocrinology Research and Clinical Developments;
- Publisher's listprice GBP 172.99
-
82 645 Ft (78 710 Ft + 5% VAT)
The price is estimated because at the time of ordering we do not know what conversion rates will apply to HUF / product currency when the book arrives. In case HUF is weaker, the price increases slightly, in case HUF is stronger, the price goes lower slightly.
- Discount 10% (cc. 8 265 Ft off)
- Discounted price 74 381 Ft (70 839 Ft + 5% VAT)
Subcribe now and take benefit of a favourable price.
Subscribe
82 645 Ft
Availability
Estimated delivery time: In stock at the publisher, but not at Prospero's office. Delivery time approx. 3-5 weeks.
Not in stock at Prospero.
Why don't you give exact delivery time?
Delivery time is estimated on our previous experiences. We give estimations only, because we order from outside Hungary, and the delivery time mainly depends on how quickly the publisher supplies the book. Faster or slower deliveries both happen, but we do our best to supply as quickly as possible.
Product details:
- Publisher Nova Medicine and Health
- Date of Publication 30 June 2025
- ISBN 9798895305874
- Binding Hardback
- No. of pages290 pages
- Size 254x178x14 mm
- Language English 675
Categories
Long description:
This book is a comprehensive academic text that delves into the complex mechanisms and therapeutic potential of various receptors and enzymes implicated in diabetes mellitus. Beginning with an in-depth introduction to the pathophysiology of diabetes mellitus, this book lays the groundwork for understanding the multifaceted nature of the disease. Each subsequent chapter is dedicated to a specific receptor or enzyme, exploring their roles in metabolic regulation, glucose homeostasis, and insulin secretion. The text covers a range of crucial targets, including free fatty acid receptors (FFAR1/GPR40 and FFAR4/GPR120), insulin receptors (IR), glucagon-like peptide-1 receptors (GLP-1R), peroxisome proliferator-activated receptors (PPARs), sodium-glucose cotransporter 2 (SGLT2) inhibitors, alpha-glucosidase inhibitors, SIRT1, 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), G-protein-coupled receptors, adenosine monophosphate-activated protein kinase (AMPK), muscarinic acetylcholine receptors (mAChRs), protein tyrosine phosphatase 1B (PTP1B), and fructose 1,6-bisphosphatase (FBPase). This book not only elaborates on the biochemical and physiological roles of these targets but also discusses the latest therapeutic strategies aimed at modulating their activity for effective diabetes management. Readers will gain insights into how these receptor-targeted therapies can enhance insulin secretion, improve glycemic control, and regulate metabolic processes. The final chapter provides a forward-looking perspective on emerging trends and future research directions in receptor-targeted diabetes therapies, emphasizing the potential of personalized medicine in transforming diabetes care. Rich in scientific detail and clinical relevance this book bridges the gap between basic research and clinical application, making it an indispensable guide for those dedicated to advancing diabetes treatment and improving patient outcomes. Whether used as an educational tool or a reference for cutting-edge research, this book promises to be an authoritative source of knowledge in the field of diabetes therapeutics. This book is designed to serve as a valuable resource for medical students, graduate students, researchers, clinicians, and healthcare professionals interested in the advanced study of diabetes and its treatments.
More
Middle Proterozoic Belt Supergroup, Western Montana: Great Falls, Montana to Spokane, Washington, July 20 - 28, 1989
8 097 HUF
7 288 HUF
Communication for Health and Behavior Change: A Developing Country Perspective
12 182 HUF
10 964 HUF